ArticleJournal of orthopaedic surgery and research2025
Dextrose prolotherapy at varying concentrations ameliorates tendon injury via IGF-2R: an integrated study of Mendelian randomization and an animal model.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The effect of dextrose prolotherapy on pain and functional outcomes in chronic shoulder pain: A systematic review and meta-analysis of randomized controlled trials.Qatar medical journal · 2026Review
- Time-Dependent Efficacy and Safety of Percutaneous Treatments for Lateral Epicondylitis: A Systematic Review and Network Meta-Analysis.Journal of pain research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThis study integrates Mendelian randomization (MR) analysis with animal experiments to systematically evaluate the therapeutic efficacy of varying concentrations of hypertonic dextrose on tendon injury and elucidate the underlying mechanisms in the context of tendon repair.
methodsThe SwissTargetPrediction database was utilized to identify potential molecular targets of dextrose. Two-sample MR analysis was performed to investigate the causal relationships between the identified targets and Achilles tendinopathy. Comprehensive in vivo experiments that included behavioral tests, histological examination (hematoxylin‒eosin staining), and molecular analyses (Western blotting and RT‒qPCR) were conducted to validate the MR findings.
resultsMR analysis revealed a significant causal association between dextrose-mediated effects and IGF-2R expression in the context of Achilles tendinopathy. In vivo studies demonstrated that tendon injury significantly impaired motor function in a rat model, with notable improvements observed after dextrose intervention. Histopathological analysis revealed that injured tendons presented disorganized collagen fiber arrangement, enhanced neovascularization, and increased cellular proliferation. Dextrose treatment at both 15% and 25% concentrations significantly improved collagen fiber organization, resulting in more compact and parallel fiber alignment. Furthermore, dextrose intervention significantly modulated the expression of molecular markers, including reduced type III collagen expression, upregulated vascular endothelial growth factor expression, and downregulated IGF-2R mRNA expression. Notably, 25% dextrose solution demonstrated superior efficacy, significantly increasing the expression of SCX, type I collagen, and transforming growth factor-β1.
conclusionHypertonic dextrose downregulates IGF-2R expression, upregulates vascular endothelial growth factor and transforming growth factor-β1 expression, modulates collagen synthesis, increases type I collagen content, and accelerates tendon healing. Among the tested concentrations, 25% hypertonic glucose yielded the best therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.